Dexycu Approved to Treat Inflammation Following Cataract Surgery
February 12, 2018 – The U.S. FDA has approved Dexycu™ (dexamethasone intraocular suspension), manufactured by Icon Bioscience, Inc., to treat inflammation associated with cataract surgery. The injectable medication provides a one-time treatment option for patients who undergo cataract surgery, removing the need to self-administer eye drops multiple times per day for a number of weeks following a cataract procedure.
According to Icon Bioscience, over four million cataract surgeries are performed in the United States annually. Most of these surgeries are performed on elderly patients. Dexycu is the first FDA-approved long-acting intracameral treatment for inflammation caused by cataract surgery. It may help to avoid dosing errors and nonadherence that occur when patients are required to self-administer eye drops several times a day to treat post-operative inflammation.
Dexycu is administered by the ophthalmic surgeon at the end of surgery as a single 5 mcL injection, (equivalent to 517 mcg of dexamethasone). Designed for extended release, the product delivers dexamethasone, a corticosteroid, into the posterior chamber of the eye over time.
Icon Bioscience has not yet released launch or pricing information.
Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by U.S. mail or by fax.
- Complete and submit the report Online: www.fda.gov/medwatch/report.htm
- U.S. Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
Actual drug patent expiration dates and availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval. Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval. Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.
*This is provided for information only. The reference to any medication above does not mean the medication is covered by your plan.